Frazis Capital Podcast

By Michael FrazisBusiness Investing

Frazis Capital Podcast episodes

April 06, 2025 Clarity Pharmaceuticals, with Dr Alan Taylor
00:00 Welcome Back and Market Overview03:05 Navigating the Macro Environment05:59 Company Developments and Fast Track Designations09:11 Short Selling and Market Sentiment12:08 Innovations in PSMA Targeting Agents15:03 Financing Strategies and Market Positioning17:46 Clinical Trials and Sensitivity Improvements21:14 Regulatory Pathways and Market Entry24:00 Future Prospects and Market Dynamics35:30 Market Opportunities and Product Expansion35:59 Advancements in Diagnostics and Treatment39:03 Dose Optimization and Clinical Trials43:59 Patient Responses and Safety Profiles47:02 Future Directions and Phase Three Trials50:59 Navigating the Biotech Landscape52:47 Competitor Analysis and Market Positioning57:57 Innovations in Cancer Treatment
53 min
March 30, 2025 Curing prostate cancer, with research superstar Professor Louise Emmett
00:00 - Introduction to Radiopharmaceuticals and PSMA
03:00 - Current State of PSMA in Prostate Cancer Treatment
06:04 - Comparative Analysis: US vs Australia in Radiopharmaceuticals
09:02 - Imaging Techniques and Their Impact on Diagnosis
12:14 - The Patient Journey: From Diagnosis to Treatment
14:56 - Challenges in Sensitivity and Specificity of Imaging
17:57 - Post-Treatment Monitoring and Biochemical Recurrence
21:09 - Innovations in Radiopharmaceuticals and Future Directions
23:57 - Market Dynamics and Regulatory Challenges
26:56 - Conclusion and Future of Prostate Cancer Imaging
36:05 - Advancements in Targeted Therapies for Prostate Cancer
41:12 - The Future of Combination Therapy
42:52 - Imaging Innovations in Cancer Detection
44:45 - Challenges in Treatment Approval and Reimbursement
51:46 - The Role of Multiple Targets in Cancer Therapy
54:40 - Exploring New Agents and Their Applications
01:00:14 - The Need for Improved Reimbursement Pathways
1 hr 2 min
March 22, 2025 Equity sell off - the real deal? Strategy update from Michael Frazis
Equity sell off - the real deal? Strategy update from Michael Frazis
35 min
February 26, 2025 #82: A fresh look at true customer love and explosive growth, HIMS, Clarity Pharma and semis
00:0 True Customer Love and Explosive Growth02:05 - Portfolio update04:09 - Hims: A Case Study in True Customer Love and Explosive Growth07:18 - Defining True Customer Love11:33 - The Future of Hims and Market Dynamics in GLP-1sClarity's Fast-Tracked Approval and Market Response27:06 - Short Selling in CU629:59 - If you want to be valued like a US biotech company, you have to be capitalized like one32:10 - Clarity's FDA trial timeline36:33 - Updates from Nubank and MercadoLibre 40:54 - Customer Love and Explosive Growth44:45 - Identifying Explosive Growth Opportunities52:02 - Influence of Tech Leaders on Market Trends59:30 - Long-Term Perspectives on Semiconductor Growth
36 min
January 31, 2025 #82: Ellianna joins to talk DeepSeek, winners and losers, and 2024 in review
#82: Ellianna joins to talk DeepSeek, winners and losers, and 2024 in review
45 min
January 30, 2025 #81: Deepseek Disruption
Timestamps
00:00 - The Rise of DeepSeek: A Game Changer in AI
02:52 - Impact on Valuations and Capital Expenditure
05:55 - Investment Strategies in 2025
08:52 - Focus on Australian Biotech and Healthcare
Takeaways
DeepSeek's AI system is a major disruptor in the market.
The release of model weights challenges existing AI business models.
Investors are reconsidering large investments in foundational models.
Apple and AWS may benefit from the efficiency of DeepSeek's model.
Semiconductor investments are highly cyclical and risky.
Startups may struggle to secure funding in a downturn.
Australian biotech presents interesting investment opportunities.
Clarity Pharmaceuticals is a notable player in the biotech space.
The Australian market is underperforming compared to Wall Street.
Government hiring is impacting the private sector's performance.
titles
DeepSeek, AI, investment, market impact, semiconductor, Australian biotech, valuations, data centers, technology, healthcare
11 min
December 20, 2024 #80: Aliens, Syntara and the NDIS, with Arjun Balaji
#80: Aliens, Syntara and the NDIS with Arjun Balaji
36 min
December 16, 2024 #79 Repairing Nerves with Orthocell CEO Paul Anderson
Paul Anderson, CEO of Orthocell, discusses the company's collagen-based medical devices aimed at regenerative medicine.
He covers their products for bone regeneration, nerve repair, and tendon repair, highlighting their clinical success and market potential.
The conversation also covers the company's strategic partnerships, regulatory approvals, and future plans for expansion, particularly in the U.S. market.
Paul emphasizes the company's commitment to manufacturing in Australia.
Takeaways
- Orthocell specializes in regenerative medicine with a focus on collagen-based products.
- The company has developed three main products for bone, nerve, and tendon repair.
- Their bone regeneration product is approved in multiple jurisdictions, including the U.S. and Europe.
- The nerve repair product aims to improve surgical outcomes by reducing scar tissue.
- Clinical trials have shown an 85% success rate in nerve repair surgeries.
- The market for their products is estimated to be worth $3.5 billion globally.
- Orthocell plans to enter the U.S. market with a 510(k) submission by the end of 2024.
- The company has raised $17 million to support its U.S. expansion efforts.
- Their manufacturing process is based in Australia, emphasizing local production.
- The leadership team includes experienced professionals with strong industry connections.
Chapters
00:14 - Overview of Orthocell and Its Products
03:51 - Bone Regeneration Product and Market Potential
06:28 - Nerve Repair Product: Innovation and Benefits
13:44 - Clinical Outcomes and Patient Impact
19:02 - Market Competition and Future Directions
24:13 - Entering the US Market
25:32 - Regulatory Pathways and Approvals
27:14 - Marketing Strategies and Clinical Data
29:50 - Product Differentiation and Competitive Edge
32:05 - Market Sizing and Revenue Potential
34:59 - Pricing Strategy and Economic Benefits
38:18 - Sales Distribution and Partnerships
39:32 - Financial Position and Board Strength
42:41 -Future Milestones and Expectations
Keywords
Orthocell, regenerative medicine, collagen, nerve repair, medical devices, clinical trials, market strategy, healthcare innovation, product launch, financial growth
46 min
December 14, 2024#79 Breakout data in Myelofibrosis - Syntara CEO Gary Philips joins to discuss their breakout results
Takeaways
Syntara's recent data suggests significant improvements in myelofibrosis patients.
The company has a unique in-house drug development model.
Syntara's drug 5505 shows promise in reducing fibrosis.
The clinical trial results indicate a high percentage of responders.
There is a substantial unmet need in the treatment of myelofibrosis.
Syntara is exploring additional indications for their drug.
Investor relations are crucial for funding future studies.
The market opportunity for Syntara's drug is significant.
The company is focused on maintaining a strong safety profile for their drug.
Future studies will aim to expand the understanding of 5505's efficacy.

Chapters
00:00 Syntara’s Breakthrough in Myelofibrosis Treatment
06:02 The Future of Sintara and Its Pipeline
11:44 The Unique Drug Development Model
18:47 Understanding Myelofibrosis and Drug Mechanism
25:55 Clinical Trials and Patient Outcomes
32:35 Market Potential and Valuation Insights
37:21 Navigating Competition and Opportunities in Drug Development
39:24 Strategic Capital Raising for Future Growth
41:44 De-risking Clinical Trials and FDA Interactions
45:14 Investment Opportunities and Market Dynamics
50:54 Exploring Additional Drug Programs and Future Potential

Keywords
Syntara, myelofibrosis, biotech, clinical trials, drug development, fibrosis, investment opportunities, FDA, patient outcomes, healthcare
Summary
In this conversation, Michael Frazis discusses the significant advancements made by Syntara, particularly in relation to their drug 5505 for treating myelofibrosis. He highlights the company's unique approach to drug development, the promising results from clinical trials, and the potential market opportunities that lie ahead. The discussion also covers the challenges faced in the biotech industry, the importance of investor relations, and the future directions for Syntara's research and development efforts.
1 hr 2 min
November 29, 2024 #78 - Immutep CEO Marc Voigt discusses the latest in immunotherapy for lung cancer
Michael Frazis interviews Marc Voigt, CEO of Imutep, discussing the challenges of lung cancer, the evolution of immunotherapy, and the innovative approaches Imutep is taking in cancer treatment. They explore clinical trial data, commercial opportunities, and advancements in autoimmune disease research, while also addressing the financial health and future directions of Immutep.
00:00 Introduction to Lung Cancer and Its Challenges
02:32 Understanding Treatment Options for Lung Cancer
05:22 The Evolution of Immunotherapy
08:00 Imutep's Innovative Approach to Cancer Treatment
10:39 Clinical Trials and Promising Data
13:47 Collaboration with Merck and Future Prospects
25:48 Clinical Trials and Efficacy Analysis
28:03 Commercial Opportunities in Oncology
31:15 Acquisition Trends in Biotech
31:38 Advancements in Head and Neck Cancer Treatment
37:32 Exploring Autoimmune Disease Treatments
45:26 Financial Strategies and Investment Priorities
Keywords
lung cancer, immunotherapy, clinical trials, cancer treatment, autoimmune diseases, Imutep, Keytruda, cancer research, market opportunities, healthcare innovation
52 min